Published in Brain Res on May 29, 1995
Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci (2003) 3.64
Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther (2007) 2.51
The role of the dynorphin-kappa opioid system in the reinforcing effects of drugs of abuse. Psychopharmacology (Berl) (2010) 2.19
Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl) (2008) 1.68
Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology (2006) 1.60
Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl) (2014) 1.48
Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacology (Berl) (2005) 1.43
kappa-Opioid receptor signaling and brain reward function. Brain Res Rev (2009) 1.32
Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl) (2009) 1.32
κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci (2012) 1.29
Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev (2008) 1.26
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26
Effect of the endogenous kappa opioid agonist dynorphin A(1-17) on cocaine-evoked increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.21
A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats. Psychopharmacology (Berl) (2005) 1.20
Effects of the kappa opioid agonist U50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. Psychopharmacology (Berl) (2004) 1.20
Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. Ann N Y Acad Sci (2010) 1.16
Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav (2009) 1.11
A possible mechanism underlying the effectiveness of acupuncture in the treatment of drug addiction. Evid Based Complement Alternat Med (2008) 1.09
Kappa opioids as potential treatments for stimulant dependence. AAPS J (2005) 1.08
Functional selectivity of 6'-guanidinonaltrindole (6'-GNTI) at κ-opioid receptors in striatal neurons. J Biol Chem (2013) 1.08
A functional haplotype implicated in vulnerability to develop cocaine dependence is associated with reduced PDYN expression in human brain. Neuropsychopharmacology (2008) 1.07
Effect of the kappa opioid agonist R-84760 on cocaine-induced increases in striatal dopamine levels and cocaine-induced place preference in C57BL/6J mice. Psychopharmacology (Berl) (2004) 1.04
Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry (2012) 1.04
κ Opioid receptors in the nucleus accumbens shell mediate escalation of methamphetamine intake. J Neurosci (2015) 1.03
The kappa opioid receptor antagonist JDTic attenuates alcohol seeking and withdrawal anxiety. Addict Biol (2012) 1.03
Effects of acute and repeated administration of salvinorin A on dopamine function in the rat dorsal striatum. Psychopharmacology (Berl) (2008) 1.03
Estradiol: a key biological substrate mediating the response to cocaine in female rats. Horm Behav (2009) 1.02
Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity. Neuron (2013) 0.99
A neuropeptide-centric view of psychostimulant addiction. Br J Pharmacol (2008) 0.97
The role of kappa-opioid receptor activation in mediating antinociception and addiction. Acta Pharmacol Sin (2010) 0.95
Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse. J Nat Prod (2009) 0.94
The kappa opioid receptor: from addiction to depression, and back. Front Psychiatry (2014) 0.94
Microinjection of the delta-opioid receptor selective antagonist naltrindole 5'-isothiocyanate site specifically affects cocaine self-administration in rats responding under a progressive ratio schedule of reinforcement. Behav Brain Res (2007) 0.93
Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. J Pharmacol Exp Ther (2009) 0.90
Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models. Br J Pharmacol (2014) 0.90
Attenuation of cocaine-induced reinstatement of drug seeking in squirrel monkeys: kappa opioid and serotonergic mechanisms. Psychopharmacology (Berl) (2009) 0.90
Discovery of Small Molecule Kappa Opioid Receptor Agonist and Antagonist Chemotypes through a HTS and Hit Refinement Strategy. ACS Chem Neurosci (2012) 0.89
The macrocyclic tetrapeptide [D-Trp]CJ-15,208 produces short-acting κ opioid receptor antagonism in the CNS after oral administration. Br J Pharmacol (2013) 0.89
N-Alkyl-octahydroisoquinolin-1-one-8-carboxamides: a Novel Class of Selective, Nonbasic, Nitrogen-Containing κ-Opioid Receptor Ligands. ACS Med Chem Lett (2010) 0.88
Evaluation of the kappa-opioid receptor-selective tracer [(11)C]GR103545 in awake rhesus macaques. Eur J Nucl Med Mol Imaging (2010) 0.88
Kappa opioid receptor signaling in the brain: Circuitry and implications for treatment. Prog Neuropsychopharmacol Biol Psychiatry (2015) 0.87
Orvinols with mixed kappa/mu opioid receptor agonist activity. J Med Chem (2013) 0.87
The macrocyclic peptide natural product CJ-15,208 is orally active and prevents reinstatement of extinguished cocaine-seeking behavior. J Nat Prod (2013) 0.86
Synthesis and κ-opioid receptor activity of furan-substituted salvinorin A analogues. J Med Chem (2014) 0.85
Roles of nucleus accumbens CREB and dynorphin in dysregulation of motivation. Cold Spring Harb Perspect Med (2013) 0.85
Testosterone and nucleus accumbens dopamine in the male Syrian hamster. Psychoneuroendocrinology (2008) 0.85
Effects of the mixed mu/kappa opioid nalbuphine on cocaine-induced changes in subjective and cardiovascular responses in men. Neuropsychopharmacology (2005) 0.82
Effects of neonatal stress and morphine on kappa opioid receptor signaling. Neonatology (2009) 0.82
Structure-activity relationship studies of functionally selective kappa opioid receptor agonists that modulate ERK 1/2 phosphorylation while preserving G protein over βarrestin2 signaling bias. ACS Chem Neurosci (2015) 0.81
Salvinorin A analogs and other κ-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol (2014) 0.81
A single injection of a novel κ opioid receptor agonist salvinorin A attenuates the expression of cocaine-induced behavioral sensitization in rats. Behav Pharmacol (2012) 0.80
Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.80
Effects of ATPM-ET, a novel κ agonist with partial μ activity, on physical dependence and behavior sensitization in mice. Acta Pharmacol Sin (2010) 0.79
The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us? Br J Pharmacol (2012) 0.79
The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats. Eur J Pharmacol (2013) 0.78
Effects of combined opioids on pain and mood in mammals. Pain Res Treat (2012) 0.78
Effects of the kappa opioid receptor antagonist nor-binaltorphimine (nor-BNI) on cocaine versus food choice and extended-access cocaine intake in rhesus monkeys. Addict Biol (2015) 0.78
Loss of morphine reward and dependence in mice lacking G protein-coupled receptor kinase 5. Biol Psychiatry (2014) 0.78
Fischer rats are more sensitive than Lewis rats to the suppressive effects of morphine and the aversive kappa-opioid agonist spiradoline. Behav Neurosci (2013) 0.77
[The endogenous opioid system and drug addiction]. Ann Pharm Fr (2010) 0.76
The opioid receptors as targets for drug abuse medication. Br J Pharmacol (2015) 0.75
Effects of nalfurafine on the reinforcing, thermal antinociceptive, and respiratory-depressant effects of oxycodone: modeling an abuse-deterrent opioid analgesic in rats. Psychopharmacology (Berl) (2017) 0.75
Vocal fold scarring: current concepts and management. Otolaryngol Head Neck Surg (1996) 1.77
Soil moisture redistribution as a mechanism of facilitation in savanna tree-shrub clusters. Oecologia (2005) 1.38
The effect of anaesthesia of the airway in dog and man: a study of respiratory reflexes, sensations and lung mechanics. Clin Sci Mol Med (1976) 1.36
Stereopsis and binocular vision after surgery for unilateral infantile cataract. J AAPOS (1999) 1.25
U50,488, a kappa opioid receptor agonist, attenuates cocaine-induced increases in extracellular dopamine in the nucleus accumbens of rats. Neurosci Lett (1994) 1.24
Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem (2003) 1.22
Antischistosomal drugs: past, present ... and future? Pharmacol Ther (1995) 1.20
Woody plant invasion of grasslands: establishment of honey mesquite (Prosopis glandulosa var.glandulosa) on sites differing in herbaceous biomass and grazing history. Oecologia (2013) 1.20
18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res (1996) 1.18
A new active metabolite of "Miracil D". Nature (1965) 1.15
Cellular growth state differentially regulates enterocyte gene expression in butyrate-treated HT-29 cells. Cell Growth Differ (1996) 1.13
Oxygen causes fetal pulmonary vasodilation through activation of a calcium-dependent potassium channel. Proc Natl Acad Sci U S A (1996) 1.11
Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav (1997) 1.06
kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci U S A (1996) 1.05
Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity. J Pharmacol Exp Ther (1999) 1.04
Purification of the opiate receptor from rat brain. Proc Natl Acad Sci U S A (1981) 1.04
Drug resistance in schistosomes. Parasitol Today (1993) 1.03
14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem (1993) 1.03
18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci (2000) 1.02
Sildenafil: from the bench to the bedside. CMAJ (2000) 1.02
Sedative and anxiolytic effects of zopiclone's enantiomers and metabolite. Eur J Pharmacol (2001) 1.00
Voltage-gated potassium channels in human ductus arteriosus. Lancet (2000) 1.00
The non specificity of specific nitric oxide synthase inhibitors. Biochem Biophys Res Commun (1992) 1.00
18-MC reduces methamphetamine and nicotine self-administration in rats. Neuroreport (2000) 0.99
Schistosomicidal activity of lucanthone hydrochloride, hycanthone and their metabolites in mice and hamsters. J Parasitol (1967) 0.96
Emetic activity of N-substituted norapomorphines. J Med Chem (1975) 0.96
Hycanthone, a new active metabolite of lucanthone. J Med Chem (1967) 0.95
Ring-hydroxylated analogues of lucanthone as antitumor agents. J Med Chem (1982) 0.95
Molecular mechanics modeling of oligonucleotide adducts of the antitumor drug cis-diamminedichloroplatinum(II). Biopolymers (1987) 0.95
Metabolism of remifentanil during liver transplantation. Br J Anaesth (1998) 0.94
Assignment of the appaloosa coat colour gene (LP) to equine chromosome 1. Anim Genet (2004) 0.92
Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res (1994) 0.92
The chemotherapy of schistosomiasis. Annu Rev Pharmacol Toxicol (1985) 0.92
Comparative effects of dextromethorphan and dextrorphan on morphine, methamphetamine, and nicotine self-administration in rats. Eur J Pharmacol (2001) 0.91
Naphthoquinone antimalarials. XXIX. 2-hydroxy-3-(omega-cyclohexylalkyl)-1,4-naphthoquinones. J Med Chem (1967) 0.91
Redox control of oxygen sensing in the rabbit ductus arteriosus. J Physiol (2001) 0.89
Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur J Pharmacol (1991) 0.89
A comparison of oral and parenteral activity of hycanthone and lucanthone in experimental infections with Schistosoma mansoni. Am J Trop Med Hyg (1967) 0.89
Purification and characterization of the mu opiate receptor from rat brain using affinity chromatography. Proc Natl Acad Sci U S A (1985) 0.88
Enhanced cocaine self-administration in adult rats prenatally exposed to cocaine. Neurosci Lett (1996) 0.88
Ibogaine-like effects of noribogaine in rats. Brain Res (1996) 0.88
Development of novel medications for drug addiction. The legacy of an African shrub. Ann N Y Acad Sci (2000) 0.87
4-[(Aminoalkyl)amino]-1,2-dimethoxynaphthalenes as antimalarial agents. J Med Chem (1980) 0.86
Interactions between iboga agents and methamphetamine sensitization: studies of locomotion and stereotypy in rats. Psychopharmacology (Berl) (2000) 0.85
Evidence for the mode of antischistosomal action of hycanthone. Life Sci (1985) 0.85
Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology (1992) 0.85
Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism. J Pharmacol Exp Ther (1995) 0.85
Parasympatholytic (anticholinergic) esters of the isomeric 2-tropanols. 1. Glycolates. J Med Chem (1977) 0.85
Ibogaine neurotoxicity: a re-evaluation. Brain Res (1996) 0.85
An analysis of multiple mechanisms of adenosine toxicity in baby hamster kidney cells. J Cell Physiol (1985) 0.84
An oral self-administration model of nicotine preference in rats: effects of mecamylamine. Psychopharmacology (Berl) (1996) 0.84
Synthesis and characterization of 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene (BODIPY)-labeled fluorescent ligands for the mu opioid receptor. Biochem Pharmacol (1997) 0.84
Long-acting contraceptive agents: design of the WHO Chemical Synthesis Programme. Steroids (1983) 0.83
Effects of prenatal cocaine exposure on the nigrostriatal dopamine system: an in vivo microdialysis study in the rat. Brain Res (1994) 0.83
18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology (Berl) (1998) 0.83
Torsional motion and elasticity of the deoxyribonucleic acid double helix and its nucleosomal complexes. Biochemistry (1982) 0.83
Hycanthone resistance in schistosomes correlates with the lack of an enzymatic activity which produces the covalent binding of hycanthone to parasite macromolecules. Mol Biochem Parasitol (1992) 0.83
Iboga compounds reverse the behavioural disinhibiting and corticosterone effects of acute methamphetamine: Implications for their antiaddictive properties. Pharmacol Biochem Behav (2001) 0.83
Synthesis of enantiomerically pure (+)- and (-)-18-methoxycoronaridine hydrochloride and their preliminary assessment as anti-addictive agents. Bioorg Med Chem Lett (2000) 0.82
Craniofacial electromyogram activation response: another indicator of anesthetic depth. J Clin Monit Comput (1998) 0.81
Narcotic antagonists. Fortschr Arzneimittelforsch (1965) 0.81
Enantioselective behavioral effects of sibutramine metabolites. Eur J Pharmacol (2000) 0.81
Preparation and schistosomicidal activity of some 4-hydroxymethyl-3-chloroanilines. J Med Chem (1967) 0.81
Identification of kappa opioid receptors in the immune system by indirect immunofluorescence. Proc Natl Acad Sci U S A (1995) 0.81
Binding of oxamniquine to the DNA of schistosomes. Trans R Soc Trop Med Hyg (1990) 0.81
Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol (2001) 0.81
Within-subject sensitization of striatal dopamine release after a single injection of cocaine: an in vivo microdialysis study. Synapse (1992) 0.80
Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res (1997) 0.79
Basal and amphetamine-induced asymmetries in striatal dopamine release and metabolism: bilateral in vivo microdialysis in normal rats. Brain Res (1988) 0.79
Effects of cyclazocine on cocaine self-administration in rats. Eur J Pharmacol (1998) 0.79
The potential anti-addictive agent, 18-methoxycoronaridine, blocks the sensitized locomotor and dopamine responses produced by repeated morphine treatment. Brain Res (2000) 0.78
Interactions between 18-methoxycoronaridine (18-MC) and cocaine: dissociation of behavioural and neurochemical sensitization. Brain Res (2000) 0.78
Postsynaptic localization and up-regulation of serotonin 5-HT1D receptors in rat brain. Brain Res (1989) 0.78
Analysis of a SNP in exon 7 of equine OCA2 and its exclusion as a cause for appaloosa spotting. Anim Genet (2006) 0.78
Traumatic aneurysm of a common digital artery--a case report. J Hand Surg Am (1982) 0.78
Binding of tritiated hycanthone and hycanthone N-methylcarbamate to macromolecules of drug-sensitive and drug-resistant schistosomes. Mol Biochem Parasitol (1988) 0.78
Behavioural sensitization to cocaine is dissociated from changes in striatal NMDA receptor levels. Neuroreport (2000) 0.78
Prior morphine exposure enhances ibogaine antagonism of morphine-induced dopamine release in rats. Neuropharmacology (1996) 0.77
Recent progress in the chemotherapy of schistosomiasis. Prog Drug Res (1974) 0.77
Ibogaine enhances the expression of locomotor sensitization in rats chronically treated with cocaine. Pharmacol Biochem Behav (1999) 0.77
5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists. J Pharmacol Exp Ther (1994) 0.77
Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats. Brain Res (1998) 0.77
Lactic acidosis B associated with solid tumors. Minn Med (1986) 0.77
14 beta-(2-bromoacetamido)morphine and 14 beta-(2-bromoacetamido)morphinone. J Med Chem (1983) 0.77
Synthesis, rodent biodistribution, dosimetry, metabolism, and monkey images of carbon-11-labeled (+)-2 alpha-tropanyl benzilate: a central muscarinic receptor imaging agent. J Nucl Med (1992) 0.77
Iboga interactions with psychomotor stimulants: panacea in the paradox? Toxicon (2001) 0.77
Fluorescent staining of kappa opioid receptors using naltrexamine derivatives and phycoerythrin. J Immunol Methods (1997) 0.77
Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. Eur J Pharmacol (2000) 0.77
14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists. Eur J Pharmacol (1997) 0.77
Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys. J Pharmacol Exp Ther (1996) 0.76
Phase I and pharmacokinetic study of high volume intraperitoneal aclacinomycin-A (Aclarubicin). Invest New Drugs (1987) 0.76
An outbreak of mycoplasma pneumoniae respiratory illness in a semi-closed religious commune. Ann Emerg Med (1982) 0.76
Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). J Pharmacol Exp Ther (1992) 0.76
14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes. Biochemistry (1989) 0.76
18-Methoxycoronaridine differentially alters the sensitized behavioral and dopaminergic responses to repeated cocaine and morphine administration. Implications for sensitization in the mediation of drug addiction. Ann N Y Acad Sci (2000) 0.76
Neurochemical predisposition to self-administer cocaine in rats: individual differences in dopamine and its metabolites. Brain Res (1994) 0.76
Historical perspective on the chemistry and development of naltrexone. NIDA Res Monogr (1981) 0.76
N-methylcarbamate derivatives of ellipticine and olivacine with cytotoxic activity against four human lung cancer cell lines. J Med Chem (1992) 0.76